pharmaphorum

OCTOBER 5, 2022

million grant by the US government to develop an intranasal vaccine for gonorrhoea, a sexually-transmitted infection that is on the rise around the world. Some gonorrhoea infections have become untreatable with all seven main antibiotic classes – a situation last encountered in the 1920s before the advent of effective drugs for the bacterium.

Vaccination 90

Vaccination Vaccine Immune Response Bacterium 90

pharmaphorum

SEPTEMBER 10, 2020

The programme is still in the early stages of development, but if it works in trials would provide another approach to prevent transmission of SARS-CoV-2, the virus that causes COVID-19, alongside vaccines and prophylactic antibodies. The post Non-vaccine nasal spray could protect against COVID-19 appeared first on.

Vaccination 124

Vaccination Vaccine Bacterium Antibody 124

pharmaphorum

DECEMBER 1, 2021

Sanofi has added to its vaccine pipeline with an agreement to acquire Austria’s Origimm Biotechnology and its vaccine-based immunotherapy for people with acne. It will highlight vaccines for pneumococcal disease, meningitis, respiratory syncytial virus (RSV), influenza, and chlamydia. Photo by Scott Webb on Unsplash.

Vaccination 83

Vaccination Vaccine Development Hormones 83

XTalks

NOVEMBER 10, 2020

Update (November 11, 2020): Quebec-based biopharmaceutical company Medicago has announced positive results from a Phase I trial of its candidate plant-derived vaccine. Interim results of the trial show that all participants developed an antibody response after two doses of the COVID-19 adjuvanted vaccine candidate.

Vaccination 52

Vaccination Vaccine Trials Immune Response 52

XTalks

JULY 28, 2021

Merck has scored US Food and Drug Administration (FDA) approval for its next-generation pneumonia vaccine Vaxneuvance that covers 15 different strains of the pneumococcal bacteria that causes the infection. Compared to Vaxneuvance’s targeting of 15 different strains of the bacterium, Pfizer’s shot protects against 20.

FDA Approval 89

FDA Approval Vaccination Vaccine Immune Response 89

pharmaphorum

JULY 14, 2021

Already facing one rival to its blockbuster pneumococcal vaccine Prevnar, Pfizer could have another to contend with, after Affinivax reported positive phase 2 results with its ASP3772 candidate – plus a new breakthrough designation from the FDA. That is equivalent to 14% of Pfizer’s total revenues.

Immune Response 52

Immune Response Vaccination Vaccine Protein 52

The Pharma Data

MAY 31, 2022

billion in potential development milestones Proposed acquisition provides access to next-generation 24-valent pneumococcal vaccine candidate in phase II development and highly innovative, MAPS TM technology Supports development of a strong portfolio of innovative vaccines and specialty medicines. GSK to pay $2.1

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

The Pharma Data

JUNE 2, 2022

Affinivax is pioneering the development of a novel class of vaccines, the most advanced of which are next-generation pneumococcal vaccines. The number of serotypes in current vaccines is limited due to the degree of immunological interference observed when using existing conjugation technologies.

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

XTalks

DECEMBER 24, 2020

From isolating SARS-CoV-2 in early January to sequencing its genome shortly thereafter and having a prototype vaccine against it within days, scientific process and progress have held steadfast throughout the pandemic. For example, investment in mRNA vaccines and viral vectors came well before January, many years before it.

Life Science 111

Life Science Vaccination Vaccine Gene 111

XTalks

AUGUST 2, 2023

With each passing year, pharmaceutical companies around the globe strive to deliver cutting-edge medicines, therapies and vaccines that impact the lives of millions. Pfizer’s Top 5 Best-Selling Drugs of 2022: 1) Comirnaty Comirnaty is an mRNA-based vaccine indicated for the prevention of COVID-19. billion in 2022. for a pediatric dose.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

NOVEMBER 26, 2020

Founded in February 2014, 4D pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease.?

Containment 52

Containment Bacterium Development Sales 52